Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Research & Development (2016 - 2026)

Ironwood Pharmaceuticals' Research & Development history spans 16 years, with the latest figure at $21.9 million for Q4 2025.

  • On a quarterly basis, Research & Development fell 13.89% to $21.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $95.1 million, a 14.62% decrease, with the full-year FY2025 number at $95.1 million, down 14.62% from a year prior.
  • Research & Development hit $21.9 million in Q4 2025 for Ironwood Pharmaceuticals, down from $22.5 million in the prior quarter.
  • Over the last five years, Research & Development for IRWD hit a ceiling of $35.7 million in Q4 2023 and a floor of $6.0 million in Q2 2023.
  • Historically, Research & Development has averaged $20.4 million across 5 years, with a median of $22.2 million in 2025.
  • Biggest five-year swings in Research & Development: tumbled 67.2% in 2022 and later surged 406.47% in 2024.
  • Tracing IRWD's Research & Development over 5 years: stood at $31.9 million in 2021, then plummeted by 67.2% to $10.4 million in 2022, then surged by 241.53% to $35.7 million in 2023, then fell by 28.83% to $25.4 million in 2024, then fell by 13.89% to $21.9 million in 2025.
  • Business Quant data shows Research & Development for IRWD at $21.9 million in Q4 2025, $22.5 million in Q3 2025, and $23.4 million in Q2 2025.